Is trastuzumab a cost-effective treatment for breast cancer?

References

• Reeder CE, Gordon D. Managing oncology costs. Am. J. Manag. Care12(S1), S3–S16 (2005).
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235, 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med.357(1), 39–51 (2007).
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd Ed. Oxford University Press, Oxford, UK (2005).
   Google Scholar
• Briggs A, Claxton K, Sculpher MJ. Decision Modeling Methods for Health Economic Evaluation. Oxford University Press, Oxford, UK (2006).
   Google Scholar
• George B, Harris A, Mitchell A. Cost–effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics19(11), 1103–1109 (2001).
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost–effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ.13(5), 437–452 (2004).
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost–effectiveness analysis in health-care resource allocation decision-making: how are cost–effectiveness thresholds expected to emerge? Value Health7(5), 518–528 (2004).
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making20(3), 332–342 (2000).
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch. Internal. Med.163, 1637–1641 (2003).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol.23, 4265–4274 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet369(9555), 29–36 (2007).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006.
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med.354(8), 809–820 (2006).
   PubMed Web of Science ®Google Scholar
• Perik PJ, De Korte MA, Van Veldhuisen DJ, Gietema JA, Sleijfer DT, De Vries EG. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Rev. Anticancer Ther.7(12), 1763–1771 (2007).
   PubMed Web of Science ®Google Scholar
• Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol.22(6), 1063–1070 (2004).
   PubMed Web of Science ®Google Scholar
• Norum J, Risberg T, Olsen JA. A Monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost–effectiveness analysis. Ann. Oncol.16(6), 909–914 (2005).
   PubMed Web of Science ®Google Scholar
• Poncet B, Bachelot T, Colin C et al. Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost–effectiveness analysis. Clin. Oncol.19(2), 162–163 (2007).
   Google Scholar
• Drummond M, Pang F. Transferability of economic evaluation results. In: Economic Evaluation in Health Care: Merging Theory with Practice. Drummond M, McGuire A (Eds). Oxford University Press, Oxford, UK (2006).
   Google Scholar
• Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost–effectiveness analysis. J. Clin. Oncol.22(5), 854–863 (2004).
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jonsson B, Rehnberg C. Cost–effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol.1, 1–11 (2008).
   Google Scholar
• Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics25(5), 429–442 (2007).
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost–effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann. Oncol.18(9), 1493–1499 (2007).
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost–effectiveness analysis of 1-year adjuvant trastuzumab ased on 2-year follow-up HERA trial data. Breast Cancer Res. Treat.109(3), 559–566 (2008).
   PubMed Web of Science ®Google Scholar
• Garrison LPJ, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost–effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer110(3), 489–498 (2007).
   PubMed Web of Science ®Google Scholar
• Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.25(6), 625–633 (2007).
   PubMed Web of Science ®Google Scholar
• Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost–effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J. Clin. Oncol.25(6), 634–641 (2007).
   PubMed Web of Science ®Google Scholar
• Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann. Oncol.17(3), 381–390 (2006).
   PubMed Web of Science ®Google Scholar
• Norum J, Olsen JA, Wist EA, Lonning PE. Trastuzumab in adjuvant breast cancer therapy: a model based cost–effectiveness analysis. Acta Oncol.46(2), 153–164 (2007).
   PubMed Web of Science ®Google Scholar
• Hind D, Pilgrim H, Ward S. Questions about adjuvant trastuzumab still remain. Lancet369(9555), 3–5 (2007).
   PubMed Web of Science ®Google Scholar
• Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: a cost–effectiveness analysis for Belgium. Health Policy.87(2), 146–159 (2008).
   PubMed Web of Science ®Google Scholar
• Lidgren M, Jönsson B, Rehnberg C, Willking N, Bergh J. Cost–effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann. Oncol.19(3), 487–495 (2008).
   PubMed Web of Science ®Google Scholar
• Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in Canada. Curr. Oncol.15(3), 136–142 (2008).
   PubMed Web of Science ®Google Scholar
• Potvin KR, Younis T, Sellon M, Barnes P, Rayson D. Patterns of trastuzumab use and cost in a single Canadian cancer institute. Presented at: 41st Annual American Society of Clinical Oncology Meeting. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar